Verastem said it will present new Phase 2 RAMP 201 molecular profiling and external control arm analyses in KRAS-mutated recurrent low-grade serous ovarian cancer. The data cover avutometinib plus defactinib in this hard-to-treat subgroup.
published
Verastem said it will present new Phase 2 RAMP 201 molecular profiling and external control arm analyses in KRAS-mutated recurrent low-grade serous ovarian cancer. The data cover avutometinib plus defactinib in this hard-to-treat subgroup.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.